

TIME (CEST)	Hofmann Hall		Dobkin de Rios Room		
1600 - 1615	GENERAL INTRODUCTION				
1615 - 1640	NICOLAS LANGLITZ - Fieldwork in Perennial Philosophy (ask him where psychedelic research is headed)	Mod: Joost Breeksema		MATT JOHNSON - Psychedelics as Behavior Change Agents	Mod: Erwin Krediet
1640 - 1645	Break 5 minutes				
1645 - 1730	MULTIDISCIPLINARY 5-MEO-DMT RESEARCH	Mod: Kim Kuypers		STATES OF CONSCIOUSNESS RESEARCH	Mod: Michiel van Elk
	RAFAEL LANCELOTTA - The Psychotherapeutic Potential of Synthetic Tryptamines: DMT, 5-MeO-DMT, and DPT			RUBEN LAUKKONEN - The phenomenology of truth: How the feeling of insight guides decisions under uncertainty	
	LYNNETTE AVERILL - The effectiveness of psychedelic treatment for cognitive impairment, PTSD, depression, anxiety, and suicidal ideation among United States Special Operations Veterans			RAPHAEL MILLIERE - The Sense of Body Ownership in Drug-Induced States	
	LIVIA GOTO SILVA - Potential effects of 5-MeO-DMT in brain insulin resistance			Q&A	
	Q&A / PANEL DISCUSSION				
1730 - 1800	30 MIN BREAK				
1800 - 1845	PSILOCYBIN-ASSISTED PSYCHOTHERAPY	Mod: Jan Mars		DMT RESEARCH	Mod: Raphaël Millière
	RENSKE BLOM - Psilocybin in patients with treatment resistant depression: first clinical experiences from a multicenter RCT			CHRIS TIMMERMAN - Mapping immersive states of consciousness: DMT and the human brain	
	GABBY AGIN-LIEBES - Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer			ENZO TAGLIAZUCCHI - The neural and psychological correlates of inhaled N,N-dimethyltryptamine (DMT) in natural and ceremonial settings	
	GUSS & SLOSHOWER - Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic platform			Q&A	
	Q&A				
1845 - 1945	LUNCH / DINNER BREAK				

TIME (CEST)	Hofmann Hall		Dobkin de Rios Room	
1945 - 2025	<p>INTEGRATION</p> <p>LUIS FERNANDO TOFOLI - An interdisciplinary discussion on the integration of the psychedelic experience</p> <p>HENRY WHITFIELD - A longitudinal multiple baseline investigation of psychedelic integration using Acceptance and Commitment Therapy</p> <p>Q&A</p>	<p>Mod: Daan Keiman</p>	<p>BEYOND SYMPTOM REDUCTION</p> <p>ALAN KOOI DAVIS - Psychedelic-occasioned decreases in trauma symptoms among people of color who have a history of racial trauma</p> <p>INGMAR GORMAN - MDMA-assisted Psychotherapy for Posttraumatic Stress Disorder: Beyond Symptom Reduction</p> <p>Q&A</p>	<p>Mod: Eric Vermetten</p>
2025 - 2035	10 MIN BREAK			
2035 - 2115	<p>PSYCHEDELIC TREATMENTS FOR ALCOHOLISM</p> <p>ELIZABETH NIELSON - Psilocybin-Assisted Treatment of Alcohol Use Disorder: Historical Context and Current Clinical Research</p> <p>BEN SESSA - MDMA-assisted Psychotherapy for Alcoholism - The World's First MDMA-for-addictions Study</p> <p>Q&A</p>	<p>Mod: Wim van den Brink</p>	<p>CHACRUNA-PANEL - Diversity, Equity and Access in Psychedelic Medicine</p> <p>Alex Belser, Monnica Williams, NiCole Buchanan</p>	<p>Mod: Bia Labate</p>
2115 - 2125	10 MIN BREAK			
2125 - 2210	<p>SETTING</p> <p>IDO HARTOGSOHN - Psychedelics, Set and setting, Meaning-Enhancement and Placebo Response</p> <p>MENDEL KAELEN - Music as Psychedelic Therapy</p> <p>Q&A</p>	<p>Mod: David de Wied</p>	<p>TBD</p>	

SATURDAY 26 SEPTEMBER

CEST	Hofmann Hall		Dobkin de Rios Room		Shulgin Stage	
1600 - 1640	PSILOCYBIN FOR DEPRESSION: INSIDE PERSPECTIVES		HISTORICAL CONTEXTS		MICRODOSING I	
	MICHELLE BAKER-JONES - therapist perspectives	Mod: Jan Mars	WOUTER HANEGRAAFF - Psychedelics as Rejected Knowledge	Mod: Stephen Snelders	TOBIAS BUCHBORN - Introduction to the pharmacodynamics of repeated psychedelic-drug intake(15min)	Mod: Torsten Passie
	MATT JACKSON - patient perspective		JOS TEN BERGE - Drugs in Art: Instant Inspiration or Placebo?		NEILOUFAR FAMILY - Safety, tolerability & pharmacology of low dose LSD in healthy volunteers (15min)	
1640 - 1650	10 MIN BREAK					
1650 - 1735	PSYCHEDELIC & PSYCHOLYTIC THERAPY		PSILOCYBIN NEUROSCIENCE		MICRODOSING II	
	PETER GASSER - The development of psycholytic / psychedelic therapy	Mod: Robert Schoevers	KATRIN PRELLER - Psilocybin induces time-dependent changes in global brain connectivity	Mod: Katrin Preller	NADIA HUTTEN - Cognitive and subjective effects of different low 'micro' doses of LSD in a placebo-controlled study (15 min)	Mod: Kim Kuypers
	TORSTEN PASSIE - Low-dose psycholytic therapy: A neglected approach?		MARTIN MADSEN - Five-hour fMRI mapping after oral psilocybin reveals distinct psilocin-dependent changes in resting state functional connectivity		MICHIEL VAN ELK - Effects of Psilocybin Microdosing on Awe and Aesthetic Experiences: a double-blind placebo-controlled study (15 min)	
			NATASHA MASON - Acute effects of psilocybin on glutamate concentrations levels, functional connectivity, and subjective state: a placebo-controlled experimental study in humans		BALAZS SZIGETI - Beyond the placebo? An exploration of microdosing with self-blinding methodology	
			Q&A / Webinar Style		Q&A / Webinar Style	
1735 - 1800	25 MIN BREAK					
1800 - 1845	MODELS IN PSYCHEDELIC THERAPY		KEYNOTE		ETHICS AND TRANSPARENCY IN PSYCHEDELIC RESEARCH	
	IDO SIEMION - The Hakomi Method in Psychedelic Therapy: Foundational Principles and Somatic Interventions	Mod: Janis Phelps	WADE DAVIS	Mod: Olivia Rose Marcus	LUIS SIQUEIRA VALENCIO - The Role of Research Ethics in the "Psychedelic Renaissance"	Mod: TBD
	DAAN KEIMAN - Psychedelic Chaplaincy - Model For Spiritual Care and Chaplaincy That Can Supplement Psychedelic Psychotherapy and Inform Psychedelic Science				MICHIEL VAN ELK - Replication & Open Science in Psychedelic Research	
	TIM READ - The Dark Place - Developing a Comprehensive Model for Psychedelic-Assisted Psychotherapy					

SATURDAY 26 SEPTEMBER

CEST	Hofmann Hall		Dobkin de Rios Room		Shulgin Stage	
1845 - 1945	LUNCH / DINNER BREAK					
1945 - 2030	PANEL - THERAPEUTIC FRAMEWORKS	Mod: Jeff Guss	ECODELICS	Mod: Angela Ruiz	PSYCHOMETRICS	
	PANEL Therapeutic frameworks (Anne Wagner, Ros Watts, Michael Mithoefer)		SAM GANDY - From Egoism to Ecoism: Psychedelics & Nature Connection		CAMILLA DAY - Development of a Compassion Experience Scale in Psilocybin with psychological support for Treatment Resistant Depression	Mod: Flora Moujaes
			DAVID LUKE - Transpersonal ecodelia: Surveying psychedelically induced biophilia		RICARDA EVENS - The Afterglow Inventory (AGI) – a new instrument to measure subacute effects of the psychedelic experience	
			Q&A		Q&A	
2030 - 2040	10 MIN BREAK		10 MIN BREAK			
2040 - 2115	THERAPIST TRAINING	Mod: Ido Siemion	PIONEERS IN PSYCHEDELIC RESEARCH	Mod: TBD	HUMANITIES	
	Panelists TBA SOON		RICK DOBLIN - FDA and EMA Drug Development of MDMA-assisted Psychotherapy for PTSD, and Beyond		JANI PESTANEN - Sailors Of The Mind And Soul: Investigating the motivations and modalities of psychedelic substance use in the Reddit psychonaut community	Mod: Patricia Pisters
			TBD		MARC TUTERS - Silicon Valley Psychedelia, Then and Now	
2115 - 2125	10 MIN BREAK		10 MIN BREAK			
2125 - 2215	PANEL THERAPIST COMPETENCIES & TRAINING	Mod: Ido Siemion	MAINSTREAMING PSYCHEDELICS	Mod: Patricia Pisters	PHILOSOPHY	
	Panelists TBA SOON		Erik Davis, Neşe Devenot, TBD		DAAN OOSTVEEN - Towards a new materialism in psychedelics studies	Mod: Nicolas Langlitz
					AIDAN LYON - Attention: A unified, philosophical account of the mind-revealing effects of psychedelics and meditation	
					Q&A	

SUNDAY 27 SEPTEMBER

TIME (CEST)	Hofmann Hall		Dobkin de Rios Room	
1600 - 1640	MDMA FOR PTSD	Mod: Eric Vermetten	RELATIONAL EFFECTS OF AYAHUASCA	Mod: Lela Mosemghvdlshvili
	MICHAEL MITHOEFER - MDMA-assisted Psychotherapy for PTSD – Update and Observations from Clinical Trials PEDRAM DARA - Patient Perspectives on MDMA-Assisted Psychotherapy for PTSD		ADAM ARONOVICH - Ayahuasca as Relational Medicine: Intimate encounters at the frontiers of liquid modernity LEOR ROSEMAN - Palestinians, Israelis, and Ayahuasca: can psychedelics promote reconciliation?	
	Q&A		Q&A	
1640 - 1650	10 MIN BREAK			
1650 - 1730	UNDERSTANDING MECHANISMS OF CHANGE	Mod: Erwin Krediet	AYAHUASCA RESEARCH	Mod: Anja Loizaga-Velder
	TAYLOR LYONS - The acute and long-term effects of psilocybin in healthy volunteers		SIMON RUFFELL - Modulatory Effects of Ayahuasca on Personality Structure in an Adapted Traditional Framework	
	RICHARD ZEIFMAN - How Does Psilocybin Therapy Work? Exploring Experiential Avoidance as a Mechanism of Change		MALIN UTHAUG - Mind or matter? A placebo-controlled study of the effects of ayahuasca ingestion on mental health of participants in a naturalistic, neo-shamanic setting.	
	NICOLE AMADA - Narrative Self and the Psychedelic Experience: An exploratory qualitative study		HELLE KAASIK - Varieties of chemical composition of ayahuasca	
	Q&A		Discussion. Anja to ask questions	
1735 - 1800	25 MIN BREAK			
1800 - 1845	PANEL: CLINICAL USES OF KETAMINE	Mod: Tijmen Bostoën	BRINGING THE LAB TO AYAHUASCA	Mod: Emilia Sanabria
	Veronika Gold, Elias Dakwar, Raquel Bennett, Robert Schoevers		TOMAS PALENICEK - Expedition Neuron: a journey towards the neurobiology of ayahuasca in a naturalistic setting	
			EDUARDO SCHENBERG - Between Science and Eco-Awareness: Bringing the Lab to Ayahuasca	
		LEOPARDO YAWA BANE - The uses of Nixi pae in the Huni Kui tradition		

SUNDAY 27 SEPTEMBER

1845 - 1945	LUNCH / DINNER BREAK			
1945 - 2025	CLINICAL APPLICATIONS OF PSILOCYBIN			QUALITATIVE RESEARCH INTO AYAHUASCA
	"VINCENT VERROUST - The first clinical trials of psilocybin in France (1956 - 1960) "	Mod: Matthew Johnson		LUCAS OLIVEIRA MAIA - Therapeutic effects of ayahuasca ritual use as experienced by people facing severe physical illness: a qualitative study
	EMMANUELLE SCHINDLER - Preliminary analysis of the preventive effects of a single low oral dose of psilocybin in migraine headache			ANJA LOIZAGA-VELDER - The contribution of indigenous plant medicine traditions to modern psychedelic medicine
	FRANCISCO MORENO - Psilocybin versus placebo in Treatment Resistant Obsessive Compulsive Disorder			Q&A
2025 - 2035	10 MIN BREAK			
2035 - 2115	TBD	Mod: TBD		AYAHUASCA FOR MENTAL HEALTH
				MILAN SCHEIDEGGER - Developing pharmahuasca applications for mental health
				FERNANDA PALHANO-FONTES - New findings from a randomized placebo-controlled trial with ayahuasca for treatment-resistant depression
				Q&A
2115 - 2125	10 MIN BREAK			
2125 - 2215	MEDICALIZING PSYCHEDELICS			GLOBALIZATION OF AYAHUASCA: ECONOMY, ETHICS, AND POLITICS
	Bennett Zellner, Will Hall, TBA	Mod: Tehseen Noorani		DAVID DUPUIS - Shaping the hallucinogenic experience. Cultural priors, social interactions and contextual factors in the use of ayahuasca
				OLIVIA ROSE MARCUS - Traditionalizing global forms: ethics in vegetalista practices of the Peruvian Amazon
				DANIELA PELUSO - The emergence of global ayahuasca: from local entrepreneurship to an industry - with reflections on commodification